人类PTP1B变体的结构揭示了用于减肥治疗的向性位点
Aliki Perdikari1, Virgil A Woods2,3, Ali Ebrahim2
1University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science & Addenbrooke's Hospital; Cambridge, CB2 0QQ, UK.
bioRxiv : the preprint server for biology
|August 16, 2024
概括
蛋白氨酸酸酶1B (PTP1B) 的罕见变异会损害其功能,揭示新的全位. 这些发现为开发新型肥胖治疗提供了潜在的目标.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 遗传学 遗传学 是一个
背景情况:
- 蛋白氨酸酸酶1B (PTP1B) 负面调节了瘦素的信号传递.
- 抑制PTP1B在预防小鼠模型中饮食诱导的肥胖方面表现有前途.
研究的目的:
- 为了结构性地描述人类的PTP1B变体,以确定减肥疗法的全位.
- 为了研究在持久瘦身的个体中发现的罕见PTP1B变异的功能影响.
主要方法:
- 从人类外体中鉴定出12种罕见的PTP1B变异的功能性特征.
- 在体外酶活性测定,X射线结晶学和-交换质谱学 (HDX-MS).
- 在人类细胞中分析叶丁刺激的STAT3酸化.
主要成果:
- 在12种变异中,有7种表现出PTP1B功能受损,导致STAT3酸化增加.
- 结构分析揭示了PTP1B固有的全网络,与已知的机制不同.
- 关键的变异地点被确定为高度可粘合的表面区域.
结论:
- 在PTP1B中发现的全osteric网络为药物设计提供了新的机会.
- 可以开发有针对性的全性PTP1B抑制剂,以有效治疗肥胖.
- 了解PTP1B变异结构将为代谢障碍的未来治疗策略提供信息.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149


